Article
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Neuro-oncology - 1 Feb 2017
Wahl Michael, Phillips Joanna J, Molinaro Annette M, Lin Yi, Perry Arie, Haas-Kogan Daphne A, Costello Joseph F, Dayal Manisha, Butowski Nicholas, Clarke Jennifer L, Prados Michael, Nelson Sarah, Berger Mitchel S, Chang Susan M
Abstract excerpt
Background: Optimal adjuvant management of adult low-grade gliomas is controversial. Recently described tumor classification based on molecular subtype has the potential to individualize adjuvant therapy but has not yet been evaluated as part of a prospective trial. Methods: Patients aged 18 or older with newly diagnosed World Health Organization grade II low-grade gliomas and gross residual disease after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.